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Background: Fabry disease (FD) is an underdiagnosed cause of stroke in young
adults, but the frequency of this association is largely unknown. We estimated
the prevalence of FD in a nationwide cohort of young adults who had stroke and
transient ischemic attack (TIA) in Argentina. Methods: This was a prospective, mul-
ticenter study of stroke and FD in young adults (18-55 years) conducted in Argentina
between 2011 and 2015. Patients were enrolled if they had had a TIA or an isch-
emic or hemorrhagic stroke within the previous 180 days. FD was diagnosed by
measuring α-galactosidase A activity (males) and through genetic studies (females).
Results: We enrolled 311 patients (54% men, mean age: 41 years). Ischemic events
occurred in 89% of patients (80% infarcts, 9% TIA) and hemorrhagic strokes in
11%. One female (.3% of the total group, 1% of the cryptogenic ischemic strokes)
had the pathogenic mutation c.888G>A/p.Met296Ile /Exon 6 on the GAL gene.
Her only other manifestation of FD was angiokeratoma. Eighteen females had
nonpathogenic intronic variations: c.-10C>T, c.-12G>A, or both. Two patients had
the nonpathogenic mutation D313Y, while a third had the likely benign muta-
tion S126G. Conclusions: FD was identified in 1 patient (.3%) in this first Latin
American study. The patient presented with a late-onset oligo-symptomatic form
of the disease. A large number of nonpathogenic mutations were present in our
cohort, and it is essential that they not be mistaken for pathogenic mutations to
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Introduction
Stroke is a leading cause of death and disability
worldwide.1 From 5% to 10% of all strokes occur in pa-
tients under 45 years old, generating considerable morbidity
and mortality in this age group. The crude annual inci-
dence rate of stroke in young adults is estimated at between
8 and 19 per 100,000,2 whereas mortality rates range
between 2.9% at 1 year and 26.8% after 20 years.3 The
causes of stroke in this group are very diverse but remain
undetermined in up to 40% of patients after extensive
workup.4 Moreover, only limited information exists re-
garding stroke in young adults in Latin America.5-9
Fabry disease (FD) is an X-linked lysosomal storage
disorder characterized by decreased or absent activity of
lysosomal enzyme α-galactosidase A (α-GAL A); it has
been identified as an underdiagnosed etiology of stroke
in the young.10 The prevalence of CVA in FD patients iden-
tified in the Fabry Outcome Survey (FOS) was 11% in
males and 15% in females, a prevalence 12 times higher
than observed in a comparable non-Fabry population.11
In the global Fabry Registry, 6.9% of males and 4.3% of
females with FD had had an ischemic or hemorrhagic
stroke. Furthermore, 50% of males and 38% of females
had their stroke before the diagnosis of FD was made.12
Among patients with FD and no history of stroke or tran-
sient ischemic attack (TIA), 44% had silent brain infarcts
on brain magnetic resonance imaging (MRI).13 Rolfs et al
reported that 4.9% of males and 2.4% of females with
cryptogenic stroke younger than 55 years suffered from
FD, which corresponds to approximately 1.2% of young
stroke patients overall.10
Several other studies screening for FD in young stroke
patients throughout the world have yielded conflicting
results.14-22 We herein report the Argentinean Initiative for
the Study of Young patients with Stroke and Fabry disease
(AISYF Study), the first national, multicenter, prospec-
tive study to investigate the association between stroke
and FD in young Latin American adults.
Methods
Study Design and Patient Selection
We performed a prospective, multicenter, nationwide
study of ischemic and hemorrhagic stroke and FD in young
adults in Argentina. The study was conducted at 22 centers
across the country, coordinated by the Department of Neu-
rology at Hospital Británico de Buenos Aires between
January 2011 and December 2015. Patient enrollment re-
quired written informed consent.
We ultimately enrolled 311 patients between the ages
of 18 and 55 years with either a TIA (defined as a tran-
sient episode of neurological dysfunction caused by focal
brain, spinal cord, or retinal ischemia, without acute
infarction),23 an acute ischemic stroke (defined as a focal
neurological deficit due to infarction of central nervous
system tissue),23 or an intracerebral hemorrhage (defined
as a focal neurological deficit associated with focal col-
lection of blood within the brain parenchyma).24 Patients
were enrolled within 180 days of their cerebrovascular
event. We excluded patients with ischemic stroke fol-
lowing subarachnoid hemorrhage, cancer, or trauma, as
well as patients with a hemorrhagic stroke due to a vas-
cular malformation (e.g., aneurysm, arteriovenous
malformation, or cavernous hemangioma) or when sus-
pected to be related to cancer, trauma, or anticoagulation.
We also excluded patients with either an epidural or sub-
dural hemorrhage.
Stroke Subtype Classification and Etiological Workup
After informed consent was obtained from the pa-
tients, demographic data, cardiovascular risk factors, the
presence of signs and symptoms of FD, and clinical and
neuroimaging data were registered in a database. Head
computed tomography or MRI had been performed in all
patients before enrollment. After enrollment, all patients
underwent comprehensive etiological investigations, in-
cluding brain and vascular imaging, electrocardiography,
echocardiography, extensive laboratory testing, and FD en-
zymatic and genetic studies. Information on comorbidities
and vascular risk factors were collected prospectively using
a standardized prespecified case report form. All vari-
ables analyzed were checked for completeness, range, and
outliers. Trial of ORG 10172 in acute stroke (TOAST) cri-
teria were used to define the clinical subtypes of ischemic
stroke.25 Intracerebral hemorrhage was categorized by
location.24,26 Demographic information and comorbid con-
ditions of our patients will be reported separately.
Diagnosis of Fabry Disease
Measurement of α-GAL A activity (in all males) was
determined using dried blood spots on filter paper27 and
performed at the Instituto de Estudios Inmunológicos y
Fisiopatológicos (IIFP) Facultad de Ciencias Exactas,
Universidad Nacional de La Plata-Consejo Nacional de
Investigaciones Científicas y Técnicas, La Plata, Argen-
tina. When deficient activity was detected, confirmation
of the enzymatic result was performed in leukocytes from
whole blood. Sequencing of the GLA gene was per-
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formed in all females and males with deficient enzyme
activity.
The first 43% of our patients were analyzed at the
Albrecht-Kossel-Institute, Medical Faculty of the Univer-
sity Rostock, with identical procedures used in the Stroke
in young Fabry patients (SIFAP) study. The remaining
57% of the samples, analyzed in IIFP, used identical genetic
evaluation as the first half, based on sequence analysis
of coding regions of 7 exons along with intron–exon bound-
aries of the GAL gene.
Results
A total of 311 patients were enrolled (54% men, mean
age: 41years). Ischemic strokes had occurred in 89% of
the patients (infarcts 80%, TIA 9%) and hemorrhagic strokes
in 11%.
Stroke subtypes based on the TOAST classification
system25 were: atherosclerosis of large vessels, n = 33
(12.3%); cardiac embolic source, n = 20 (7.5%); small artery
occlusion, n = 31 (11.5%); other determined cause, n = 73
(27.1%); and undetermined cause: 2 or more etiologies,
n = 16 (5.9%); negative investigation, n = 55 (20.4%) and
incomplete investigation, n = 41 (15.2%). There were 19
patients with recurrent strokes and 17 with recurrent TIA.
The epidemiological characteristics of this group will
be reported separately.
We identified only 1 patient (.3% of the total sample,
1% of the patients with cryptogenic ischemic strokes) with
a pathogenic mutation: c.888G>A / p.Met296Ile / Exon
6. A second patient was identified with a previously con-
sidered pathogenic mutation c.376A>G / p.Ser126Gly /
Exon 3. In addition, 21 females had nonpathogenic mu-
tations including c.-10C>T (10 patients); c.937G>T and
p.Asp313Tyr (D313Y) (2 patients); c.-12G>A (8 patients);
and both c.-10C>T and c.-12G>A (1 patient).28,29
Patient with Pathogenic Mutation c.888G>A /
p.Met296Ile / Exon 6
A 48-year-old woman was referred to us with acute
left hemiparesis. Risk factors included hypertension and
smoking. Brain MRI revealed bilateral hyperintense lesions
in the corona radiata (Fig 1). Electrocardiography and
echocardiography were normal, as were trombophilic
studies. The patient had no neuropathic pain or cornea
verticillata but had angiokeratomas. Enzymatic studies
for FD were normal, and a genetic study identified a G
to A transition at nucleotide 888 in exon 6 of the coding
sequence, which predicted the substitution of isoleucine
for methionine at residue 296 (Met296Ile). On family
history, both the father and paternal grandmother of
the patient had suffered a stroke in their 50s. She also
had a paternal uncle with end-stage renal disease of
unclear etiology. Evaluation of her uncle and the rest of
her family identified 10 additional patients with FD; 3
are currently on enzyme replacement treatment (ERT)
(Fig 2 and Table 1).
Patient with a Mutation of Unclear Significance
c.376A>G / p.Ser126Gly / Exon 3
A 26-year-old female presented with acute left hemiple-
gia and dysarthria. She had a medical history of migraine,
use of oral contraceptives, and recent neck manipula-
tions. On admission, she had dysarthria, left hemiplegia,
and hemianopsia. Brain MRI revealed a large, right fron-
toparietal infarction with dissection of the right internal
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Figure 1. Pedigree of the family with the p.Met296Ile mutation. Square:
male; Circle: female; Filled: affected; Arrow: proband.
Figure 2. Brain magnetic resonance imaging of patient with p.Met296Ile mutation. Fluid attenuation inversion recovery. Deep small-vessel disease and
confluent white matter lesions.
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consciousness declined due to intracranial hyperten-
sion; consequently, an urgent right craniectomy was
performed, after which her mental status improved. Four
days later, she became comatose, and a new brain MRI
and angiography demonstrated cerebral venous throm-
bosis. Prothrombotic tests were performed, and
anticardiolipin antibodies and Factor V Leiden were iden-
tified. The patient was anticoagulated. FD was evaluated
as part of the AISYF protocol: α-GAL A enzyme activi-
ty, both in dried blood spots and leukocytes, was normal,
whereas genetic testing revealed a heterozygous muta-
tion in the GLA gene: S126G. Both renal and cardiac
function of the patient were normal. Moreover, she had
no signs of classical FD, like neuropathic pain, cornea
verticillata, or angiokeratomas. Her MRI revealed neither
the pulvinar sign nor an enlarged basilar artery. Her father
(55 years old) also was found to have normal α-GAL A
activity in leukocytes, and the same hemizygous muta-
tion was identified; however, he also lacked any signs
or symptoms compatible with FD. Our patient progres-
sively improved. Four years later, at the time of her last
follow-up assessment, she had persistent left hemipare-
sis but was able to work.
Discussion
There is limited information regarding strokes among
young adults in Latin America. Moreover, in large studies,
the etiology of stroke remained undetermined in 16%-
32%; none of these studies included FD in their
evaluation.5,6
We identified a low prevalence of FD in young adults
with stroke: .3% of the total group and 1% of the group
with cryptogenic stroke (including patients with both: stroke
of undetermined etiology and those with an incomplete
study). The Met296Ile mutation of our proband was as-
sociated with late-onset FD; and rather than demonstrating
the classical phenotype, this patient presented only with
stroke and angiokeratomas. The identification of 10 ad-
ditional patients in her family, who also had oligo-
symptomatic manifestations, underlines the usefulness of
screening programs in stroke patients. There is increas-
ing evidence that patients with stroke identified through
screening studies usually have mild symptoms of the disease
and that the cerebral event occurs in the absence of severe
cardiac or kidney involvement.12,20,30 MRI evidence of pre-
vious asymptomatic lesions, as our patient had, as well
as recurrent stroke before diagnosis, seems to be common
in this group.13,20 The Met296Ile mutation was originally
identified in a patient with late-onset FD, accompanied
by cardiomyopathy and hemorrhagic stroke.31
A second important finding of the current study is that
GLA gene mutations of unclear significance are common
in young patients with stroke, emphasizing the chal-
lenge of any screening study to ascertain which mutations
are pathogenic. This is essential not only to correctly iden-
tify patients with FD, but also to avoid unnecessary
treatments. The intronic mutations we found, as well as
the D113Y mutation, are currently considered nonpatho-
genic; whether they represent a risk factor for stroke is
still unclear20,22 Therefore, we did not pursue further in-
vestigations in those patients or relatives for FD signs
or symptoms.28,29
The S126G mutation is a previously reported mis-
sense mutation that results from an A to G transition at
cDNA position 376 in exon 3 of the GLA gene, which
leads to changing the amino acid serine in position 126
of the protein into glycine. This mutation has been re-
ported to be pathogenic in stroke patients.16,20 In a GAL
genetic test report, Altarescu et al described the S126G
mutation in a patient with neuropathic pain as the sole
clinical manifestation and low enzymatic activity.32 However,
Table 1. Family with FD and a pathogenic mutation c.888G>A / p.Met296Ile: Clinical manifestations
N
Age/











1 48/F no yes yes yes no no no no yes no N yes
2 47/F no no no no yes no no no no no N no
3 70/M yes yes no no no no no no no no SFN yes
4 69/F no no yes no no no no no no no SFN no
5 38/F no no yes no yes no no no no yes N no
6 43/F no yes yes yes no no no no no no SFN no
7 41/F no no no no no no no no no no N no
8 18/M no no no no no no no no no no N no
9 15/M no no no no no no no no no no N no
10 37/F no no no no no no no no no no SFN no
11 3/M no no no no no no no no no no N no
Abbreviations: A Pain, abdominal pain; Angiok, angiokeratoma; Cardio, cardiomyopathy; C Vert, cornea verticillata; Dizzin, dizziness; F,
female; Hypoac, hypoacusia; Hypoh, hypohidrosis; MRI, magnetic resonance imaging; M, Male; N pain, neuropathic pain; N, normal; Nephro,
nephropathy; QST, quantitative sensory testing; SFN, small-fiber neuropathy.
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in 2002, the same group reported this mutation in a 12-
year-old patient with no renal syndrome and the lack of
any enzymatic testing.33 More recently, in an extensive
review on GLA gene mutations, the S126G mutation was
described as a benign mutation.28
The Belgian Fabry study included a total of 1000 pa-
tients with either a first stroke (TIA, ischemic stroke, or
intracranial hemorrhage) or unexplained white matter
lesions or basilar artery dolichoectasia. The authors iden-
tified missense mutations in eight nonrelated females
(D313Y: 5 subjects, A143T: 2 subjects, S126G: 1 subject).16
However, in a later, more in-depth analysis of the index
patients and their relatives in which they evaluated 6 car-
riers (2 of them male), among those with the S126G
mutation, all 6 were found to have had completely normal
laboratory studies, including normal α-GAL A enzyme
activity in plasma and normal plasma and urinary GB3
and Lyso GB3. None of the carriers had signs or symp-
toms of classic FD. The authors concluded they could not
prove the pathogenic nature of the S126G mutation.34 Rolfs
et al recently reported the results of the SIFAP study, a
multicenter observational study that included 5023 pa-
tients with stroke. Definitive FD was detected in .5%
(n = 27). In 3 of these patients, Rolfs et al identified the
S126G mutation and suggested that it was associated with
stroke as the only manifestation of FD.20 Nevertheless, a
recent review on screening for FD concluded that none
of the individuals identified as Fabry patients in the SIFAP
study could be categorized because of insufficient data.35
Moreover, the association between a given mutation and
stroke in screening studies might be the result of selec-
tion bias.35,36 Lukas et al reported about 60% residual in
vitro activity of the S126G mutation and stated that the
pathogenic value of this mutation remains unclear.37 In
keeping with the threshold theory, only decreased enzyme
activity below the critical threshold value would result
in storage of the corresponding lipid substrate. De-
creased enzyme activity above the calculated threshold
value should not influence the turnover rate of the sub-
strate. This is because, above this threshold, there is no
linear relationship between enzyme activity and turn-
over, and pathological storage occurs only below this level.
With the exception of acid ceramidase, a decrease in
enzyme activity of more than 20% relative to normal
cells—a typical range for heterozygote carriers of inher-
ited diseases—has no impact on the turnover rate.38 Because
our proband had no other manifestations of FD and her
father was asymptomatic and had normal enzymatic values
of α-GAL A, we concluded that S126G was not a patho-
genic mutation in these two individuals.
The frequency of FD among patients with stroke is still
a controversial issue. In addition to the SIFAP study, several
screening evaluations of young patients with stroke, in-
cluding over 3000 patients from around the world, have
been published following the original German study.10,20
Inclusion criteria varied between these studies, includ-
ing young patients with stroke that were either ischemic
or hemorrhagic or both, and the presence of hyperin-
tense MRI lesions. Among these studies, 4 failed to identify
any patients with GAL gene pathogenic mutations.14,18,19,22
Among the remaining studies, 11 patients were identi-
fied with a D313Y mutation,15,16 6 had the R118C mutation,15
3 had the A143T mutation,16,17 and 1 retrospective study
identified a single patient with a combination of intronic
splice variants.21 Some of these same mutations were de-
scribed as pathogenic in the SIFAP study.20 Nevertheless,
the D313Y mutation is currently not considered clinical-
ly relevant for FD.28,29
A pedigree analysis was performed in 6 patients with
the R118C mutation. The investigators reviewed the clin-
ical, biochemical, and histopathologic data obtained from
22 individuals of Portuguese and Spanish origin with this
same mutation, and not only questioned the pathogenic
significance of this variant but also recommended not treat-
ing these patients.39 One patient with this mutation was
identified in a recent screening study for Cerebral auto-
somal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy and FD in 900 patients younger than
70 years old with a lacunar stroke. No clinical data were
available; consequently, the significance of this finding
is unclear.40
The A143T mutation was considered pathogenic in some
recently published studies.17,20 However, no family data
were provided, and no additional signs or symptoms of
FD were reported. Conversely, an in-depth study of 12
patients with the A143T mutation, including either a heart
or kidney biopsy in 3, revealed the lack of either clas-
sical signs of FD or Gb3 accumulation. The authors
suggested the possibility of selection bias.36
Similarly, 4 members of nonrelated families with A143T
were reported. The mother had left ventricular hyper-
trophy and stroke, but a cardiac biopsy was negative for
FD.41
More recently, a multicenter Italian study evaluated 350
young patients with stroke but failed to identify patho-
genic FD mutations,42 whereas a single-center study also
in Italy identified 3 patients with FD among 108 young
stroke patients. All had recurrent stroke with an oligo-
symptomatic phenotype (p.Arg301Gly, p.Leu415Arg,
p.Gly183Alafs17).30 Like our patient, they lacked the clas-
sical FD phenotype but presented with recurrent strokes
and a family history of stroke or either cardiac or kidney
involvement. Similarly, a recent study in Turkey evalu-
ated 54 patients with cryptogenic stroke. The α-GAL A
activity was low in 3 patients. c.680G>A / p.R227Q mis-
sense mutation was identified in 2 male patients with
recurrent strokes—1 presented with the classical form of
FD and the other only presented with stroke. No muta-
tion was identified in the third patient.43
The prevalence we identified in our study is similar
to the low prevalence of FD reported by the SIFAP20, the
largest study on the subject and is within the range of
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0% to .5% reported by most studies evaluating FD in young
patients with strokes.14,17-22
Although the frequency of FD among young adults with
stroke is low, the prevalence is higher when patients with
cryptogenic cerebrovascular accident are evaluated. The
late onset of symptoms and limited manifestations of FD
make their identification difficult outside of screening
studies. Moreover, once identified, these patients and their
affected relatives might benefit from ERT. Recent studies
suggest that ERT in FD patients may reduce the burden
of cerebrovascular lesions.44,45
Conclusions
In our sample of 311 young adults presenting with a
stroke or TIA, we identified FD in a single patient (.3%
of the sample and 1% of the patients with cryptogenic
ischemic strokes). Our study confirms that these pa-
tients can present with a late-onset oligo-symptomatic
phenotype. Moreover, screening young patients with cryp-
togenic strokes allows identification not only of patients
with FD but also of their affected relatives. GLA gene
nonpathogenic mutations are commonly detected in stroke-
screening studies and must not be mistaken for pathogenic
mutations. We believe that the S126G mutation should
be currently considered a nonpathogenic mutation and
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